Skip to main content

Advertisement

SpringerLink
Log in

The bladder cancer drug market

  • From the Analyst's Couch
  • Published:

From Nature Reviews Drug Discovery

View current issue Sign up to alerts

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Figure 1: US sales of biologics for bladder cancer, by drug class (estimated).

Author information

Authors and Affiliations

  1. Decision Resources Group, 9 Appold Street, London, EC2A 2AP, UK

    Khurram Nawaz & Rachel M. Webster

Authors
  1. Khurram Nawaz
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Rachel M. Webster
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Rachel M. Webster.

Ethics declarations

Competing interests

The authors declare no competing financial interests.

PowerPoint slides

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Nawaz, K., Webster, R. The bladder cancer drug market. Nat Rev Drug Discov 15, 599–600 (2016). https://doi.org/10.1038/nrd.2016.141

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1038/nrd.2016.141

  • Springer Nature Limited

Search

Navigation